Novel Bi-Specific Immuno-Modulatory Tribodies Potentiate T Cell Activation and Increase Anti-Tumor Efficacy

Cancer immunotherapy has already shown significant improvements by combining different antibodies specific for distinct immune checkpoints, such as Ipilimumab and Nivolumab. Here, we tested combinatorial treatments of immunomodulatory antibodies, previously generated in our laboratory, for their eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Passariello, Margherita, Yoshioka, Asami, Takahashi, Kota, Hashimoto, Shu-ichi, Rapuano Lembo, Rosa, Manna, Lorenzo, Nakamura, Koji, De Lorenzo, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8998846/
https://www.ncbi.nlm.nih.gov/pubmed/35408827
http://dx.doi.org/10.3390/ijms23073466

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8998846/
https://www.ncbi.nlm.nih.gov/pubmed/35408827
http://dx.doi.org/10.3390/ijms23073466

Ejemplares similares